Specifically, with Alzheimer’s disease, targeting to reduce amyloid beta plaques and phosphorylated tau aggregates in clinical trials has not yielded results to slow symptomology, suggesting a new approach is needed. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.